Abstract 394P
Background
Advanced small cell lung cancer patients have very poor outcome, with a median overall survival (OS) of less than 1 year. We conducted this phase II clinical trial to evaluate the efficacy and safety of apatinib plus etoposide capsules in the third-line or further-line treatment of patients with extensive stage small cell lung cancer.
Methods
Patients with extensive stage small cell lung cancer who failed ≥ 2 lines of therapy were recruited from 11 hospital across China. All participants should have an Eastern Cooperative Oncology Group performance status of 0 to 2, at least one evaluable lesion according to response evaluation criteria in solid tumor (RESCIST 1.1). Participants received apatinib (250mg orally every day) and etoposide capsules (50mg orally from day 1 to 21, every 4 weeks) until disease progression, death or intolerable toxicity. The primary endpoint was progression-free survival (PFS). The secondary endpoint was overall survival (OS) and safety.
Results
Totally 52 patients with a median age of 60.5 (range, 30-77) years, including 40 men (77.0%) were enrolled in our study from December 2017 to August 2019. By the end of December 2019, 45 patients progressed and 36 died. Among 52 evaluable patients, 34 patients showed a stable disease, 11 patients achieved a partial response, showing an objective response rate (ORR) of 21.2% and disease control rate (DCR) of 86.5%. The median follow-up duration was 6.6 months. The median PFS was 3.3 months (95% CI, 2.56-4.05), and median OS was 4.5 months (95% CI, 3.50-4.90). 1-year survival rate was 11.54%. Major adverse events (AEs) included leukopenia (30.77%), anemia (25%), and fatigue (19.23%). No grade 3 or more AEs were reported.
Conclusions
Apatinib plus etoposide capsules showed reasonable efficacy and toxicity among extensive stage small cell lung cancer patients in third-line or above setting. Further exploration of apatinib in phase Ⅲ trials is warranted.
Clinical trial identification
NCT03389087.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Jiangsu Hengrui Pharmaceutical Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
210P - Prognostic value of sarcopenia in metastatic renal cell carcinoma patients: A systematic review
Presenter: Angeline Tancherla
Session: e-Poster Display Session
211P - The impact of low muscle mass to overall survival in bladder cancer patients undergoing chemotherapy: A systematic review and meta-analysis
Presenter: Karunia Japar
Session: e-Poster Display Session
212P - Stage I non-seminoma testicular cancer: Adjuvant management and outcomes
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
213P - Stage I seminoma testicular cancer: Predictors of relapse and outcomes for adjuvant carboplatin vs active surveillance
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
214P - Study of treatment outcome in adults with TFE related RCC
Presenter: Ajaykumar Singh
Session: e-Poster Display Session
215P - Analysis of spatial heterogeneity of responses in metastatic sites with nivolumab in renal cell carcinoma
Presenter: Venkata Pradeep Babu Koyyala
Session: e-Poster Display Session
216P - Clinical profile and treatment outcome of testicular seminoma treated at tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
220P - A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer
Presenter: Winnie Sung
Session: e-Poster Display Session
221P - Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo (PBO) and ongoing androgen deprivation therapy (ADT) in SPARTAN
Presenter: Hiroji Uemura
Session: e-Poster Display Session
222P - Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial
Presenter: Matthew R. Smith
Session: e-Poster Display Session